Sartorius Stedim Biotech (DIM) Q4 2024 earnings summary

Executive summary

• Achieved revised 2024 guidance for revenue and profitability, with market recovery gaining momentum and robust late-year order intake; underlying growth drivers, especially consumables and advanced therapies, showed strong performance while equipment sales remained muted.

• Profitability remained robust, supported by efficiency programs that offset lower capacity utilization and led to significant cost savings.

• Lab Products & Services sales were slightly below prior year due to soft end markets, especially in China, but profitability was maintained.

• Management expects cautious, moderate, profitable growth above market rates for 2025, mainly from recurring business.

Financial highlights

• 2024 sales revenue was €3.4 billion, nearly flat year-over-year, with a 0.1% increase in constant currencies; order intake rose double digits, led by consumables.

• Underlying EBITDA margin was 28.0% (€945 million), hitting guidance midpoint; underlying EPS was €4.05 (-18.0% YoY).

• Free cash flow doubled to €550 million, driven by working capital and CapEx discipline; operating cash flow increased 14.4% to €976 million.

• CapEx ratio decreased to 12.1% from 16.5% prior year.

• Net debt reduced to €3.746 billion; leverage ratio (net debt/EBITDA) at 4.0.

Outlook and guidance

• 2025 expected to see moderate, profitable growth above market, mainly from recurring business, with Bioprocess Solutions contributing more.

• Underlying EBITDA expected to grow faster than sales due to product mix and efficiency gains.

• Quantitative guidance for FY 2025 to be provided with Q1 results; midterm targets unchanged.

• Continued focus on organic debt reduction and working capital management.